CRSP is a speculative buy for aggressive investors, driven by the commercial launch and multibillion-dollar potential of ...

Shares of CRISPR Therapeutics CRSP have rallied 41.4% in the past three months, driven by encouraging data from a study of ...

From the discovery of restriction enzymes in the 1970s to transformative CRISPR-Cas systems in the 2010s, microbial immunity has burgeoned into an incredible toolbox for genetic engineering ...

STAT reporters chat about the mood in the gene editing field, M&A deals in biotech, and leadership changes at Novo Nordisk.

CRISPR Therapeutics has rallied on Casgevy progress, but overvaluation, early-stage pipeline, and lack of profits raise ...

Argentina, widely regarded as the global capital of polo, has welcomed cloning and other breeding innovations. But CRISPR is different – for now.

Intellia is assessing the CRISPR therapy in a placebo-controlled phase 3 trial that will provide a truer test of its credentials as a challenger for the ATTR cardiomyopathy market.

Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, linking its hereditary angioedema (HAE) prospect to an 81% reduction in ...

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310 (TM) Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline June 26, 2025, 7:00 am EDT ...

Caribou Biosciences’ restructuring narrows the biotech’s focus to two off-the-shelf cell therapies for blood cancers, whose key data readouts have been pushed out to the second half of 2025 ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Adam Feuerstein is ...